Table 1.
Clinical Characteristics of Patients With SCA3 and Healthy Controls
| Parameters | Mean (SD) or n (%) | p Valuea | |||
| Healthy controls | Whole SCA3 | SCA3-SP | SCA3-NSP | ||
| Total n | 44 | 145 | 43 | 102 | |
| Sex (female) | 21 (47.7) | 57 (39.3) | 18 (41.9) | 39 (38.2) | 0.683 |
| Age at examination, y | 41.86 (11.37) | 44.50 (13.04) | 37.58 (11.72) | 47.42 (12.50) | <0.001 |
| Age at onset, y | NA | 35.94 (11.78) | 28.62 (10.41) | 39.03 (10.96) | <0.001 |
| Disease duration, y | NA | 8.779 (5.057) | 8.98 (4.42) | 8.70 (5.32) | 0.455 |
| SARA scores, points | NA | 11.89 (7.064) | 14.49 (8.12) | 10.80 (6.29) | 0.005 |
| ICARS scores, points | NA | 30.54 (17.06) | 36.16 (19.50) | 28.18 (15.42) | 0.020 |
| Normal CAG repeats | NA | 19.41 (6.977) | 19.02 (7.05) | 19.57 (6.98) | 0.598 |
| Expanded CAG repeats | NA | 74.21 (4.059) | 76.12 (4.68) | 73.40 (3.48) | <0.001 |
Abbreviations: CAG = cytosine-adenine-guanine; ICARS = International Cooperative Ataxia Rating Scale; NA = not applicable; SARA = Scale for the Assessment and Rating of Ataxia; SCA3 = spinocerebellar ataxias type 3; SCA3-SP = SCA3 patients with spastic paraplegia; SCA3-NSP = SCA3 patients with nonspastic paraplegia.
Bold p value < 0.05.
a
Mann–Whitney U test or Pearson χ2 was used to compare variables between SCA3-SP and SCA3-NSP subgroups.